NASDAQ: VCEL · Life Sciences · 9 alerts · CIK 887359
Share price
$57.48Close, Nov 16
Market cap
$2.93B
Shares outstanding
51.03MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vericel Corp filings on SEC EDGAR ↗
Vericel CFO Joseph Anthony Mara Jr. Sells $1.46M of Stock
Joseph Anthony Mara Jr., CFO, sold 25,000 shares of Vericel Corp at $58.26 a share, worth $1.46M in total on Nov 9, 2026. Shares held after the trade: 16,186 (-60.7%).
Vericel Director Kevin F. Mclaughlin Sells $413K of Stock
Kevin F. Mclaughlin, Director, sold 7,000 shares of Vericel Corp at $58.96 a share, worth $413K in total on Nov 10, 2026. Shares held after the trade: 18,300 (-27.7%).
Vericel Director Robert L. Zerbe Md. Sells $116K of Stock
Robert L. Zerbe Md., Director, sold 2,000 shares of Vericel Corp at $57.88 a share, worth $116K in total on Nov 9, 2026. Shares held after the trade: 32,995 (-5.7%).
Vericel CFO Joseph Anthony Mara Jr. Sells $2.67M of Stock
Joseph Anthony Mara Jr., CFO, sold 50,000 shares of Vericel Corp at $53.40 to $53.73 a share (average $53.48) in 4 transactions, worth $2.67M in total between Nov 5, 2026 and Nov 6, 2026. Shares held after the trade: 16,186 (-47.4%).
Vericel Principal Accounting Officer Jonathan Siegal Sells $79.3K of Stock
Jonathan Siegal, Principal Accounting Officer, sold 1,500 shares of Vericel Corp at $52.90 a share, worth $79.3K in total on Nov 5, 2026. Shares held after the trade: 1,259 (-54.4%).
Sean C. Flynn, CLO, sold 15,000 shares of Vericel Corp at $51.92 a share, worth $779K in total on Nov 5, 2026. Shares held after the trade: 1,990 (-88.3%).
Vericel Director Robert L. Zerbe Md. Sells $270K of Stock
Robert L. Zerbe Md., Director, sold 5,500 shares of Vericel Corp at $45.40 to $55.00 a share (average $49.12) in 3 transactions, worth $270K in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 32,995 (-7.0%).
Vericel Corporation reported a significant improvement in financial performance for the third quarter of 2026, with net income rising to $14.2 million compared to $5.1 million in the prior year. Total revenue for the first nine months of 2026 grew 26% to $231.3 million, driven by strong product sales, while the company transitioned from a net loss to a net income of $10.1 million for the year-to-date period.
Vericel reported third quarter 2026 total revenue growth of 26% to $85.4 million and a 179% increase in net income to $14.2 million. Driven by strong performance in its MACI and Burn Care segments, the company raised its full-year 2026 revenue guidance to a range of $344 million to $346 million.
Term
Q3 2026
“The Company delivered outstanding financial and business results in the third quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow, while also returning capital to shareholders.”
Nick Colangelo, President and CEO of Vericel
“Given our third quarter outperformance and the strong start to the fourth quarter for both commercial businesses, and particularly for MACI, we believe that the Company is very well-positioned for a strong close to 2026 and to sustain this momentum in 2027 and beyond.”